You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lower-risk MDS

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

Active, not recruiting
  • Myelodysplastic Syndromes
  • cyclophosphamide, fludarabine, and antithymocyte globulin
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023

MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Feb 16, 2023

MDS Trial (Hetrombopag)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
May 23, 2022

Lower-risk MDS Patients

Recruiting
  • MDS
    • Leipzig, Germany
      University Hospital Leipzig
    Oct 13, 2022

    MDS Trial in Tampa (Canakinumab Injection, Darbepoetin Alfa)

    Recruiting
    • Myelodysplastic Syndromes
    • Canakinumab Injection
    • Darbepoetin Alfa
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 21, 2022

    MDS Trial in Houston (Luspatercept)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 2, 2023

    Lower-risk Myelodysplastic Syndrome Trial in Tampa (JSP191)

    Recruiting
    • Lower-risk Myelodysplastic Syndrome
    • Tampa, Florida
      Moffitt Cancer Center
    Jun 20, 2023

    MDS Trial in Germany (Luspatercept)

    Recruiting
    • Myelodysplastic Syndromes
    • Hamburg, Germany
    • +4 more
    Dec 20, 2021

    Low Risk MDS Trial (R906289 Monosodium (R289 Na))

    Not yet recruiting
    • Low Risk Myelodysplastic Syndromes
    • R906289 Monosodium (R289 Na)
    • (no location specified)
    Jul 22, 2022

    MDS Trial in Worldwide (MBG453, NIS793, canakinumab)

    Recruiting
    • Myelodysplastic Syndromes
    • Duarte, California
    • +14 more
    Jan 23, 2023

    MDS Trial in Japan (Eltrombopag, Placebo)

    Recruiting
    • Myelodysplastic Syndromes
    • Narita, Chiba, Japan
    • +21 more
    Jan 19, 2023

    MDS Trial in United States (Lenalidomide, Luspatercept)

    Recruiting
    • Myelodysplastic Syndromes
    • Miami, Florida
    • +5 more
    Sep 28, 2022

    Myelodysplatic Syndromes Trial in Saint-Étienne (Physiological tests to measure fatigue level)

    Recruiting
    • Myelodysplatic Syndromes
    • Physiological tests to measure fatigue level
    • Saint-Étienne, France
      CHU de Saint-Etienne
    Feb 7, 2022

    MDS Trial (AG-946, Placebo)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • (no location specified)
    Aug 4, 2022

    MDS Trial in Boston (MBG453)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Boston, Massachusetts
    • +2 more
    Mar 28, 2021

    MDS, Anemia Trial in Germany (Luspatercept Injection)

    Recruiting
    • Myelodysplastic Syndromes
    • Anemia
    • Luspatercept Injection
    • Berlin, Germany
    • +18 more
    Jan 25, 2023

    Tumors, Solid Tumor, Adult, Non-Hodgkin Lymphoma Trial in Worldwide (JNJ-64619178)

    Active, not recruiting
    • Neoplasms
    • +3 more
    • Sarasota, Florida
    • +17 more
    Jan 27, 2023

    Primary MDS Classified as Very Low, Low or Intermediate Risk With <5% Blasts Trial in China (FG-4592, Placebo)

    Active, not recruiting
    • Primary MDS Classified as Very Low, Low or Intermediate Risk With <5% Blasts
    • Bengbu, Anhui, China
    • +37 more
    Aug 17, 2022

    Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)

    Recruiting
    • Leukemia
    • +2 more
    • Enasidenib mesylat dose escalation
    • Palo Alto, California
      Stanford Cancer Institute
    May 12, 2022

    MDS Trial (Roxadustat in combination with retinoic acid)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Roxadustat in combination with retinoic acid
    • (no location specified)
    Aug 26, 2023

    MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)

    Recruiting
    • MDS/MPN
    • Azacitidine (AZA) with Ruxolitinib
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital of Nanjing Medical University
    Apr 17, 2023

    Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) Trial in Worldwide (FG-4592, Placebo)

    Active, not recruiting
    • Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
    • Los Angeles, California
    • +71 more
    Sep 16, 2022

    Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Neoplasm
    • (no location specified)
    Apr 24, 2023

    MDS Over Time - Comparison of Treated vs Untreated Patients

    Completed
    • Myelodysplastic Syndromes
      • Vienna, Austria
        Hanusch Krankenhaus, 3.Medizinische Abteilung
      Nov 21, 2022